Login to Your Account

Anaeropharma nets $13.2M for bacteria-based approach in cancer, ischemic disease

By David Ho
Staff Writer

Monday, July 10, 2017

HONG KONG – With $13.2 million in new financing, Tokyo-based oncology drug developer Anaeropharma Science Inc. now plans to focus on research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant Bifidobacterium.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription